Moreover, in the PALOMA3 study PIK3CA status in cfDNA did not show to significantly affect neither the magnitude of benefit associated with fulvestrant plus palbociclib nor the hormone-receptor status of BC [87]. The gene discussed is PIK3CA; the disease is breast cancer.